DOI QR코드

DOI QR Code

Efficiency and Side Effects of Sorafenib Therapy for Advanced Hepatocellular Carcinoma: A Retrospective Study by the Anatolian Society of Medical Oncology

Berk, Veli;Kaplan, Mehmet Ali;Tonyali, Onder;Buyukberber, Suleyman;Balakan, Ozan;Ozkan, Metin;Demirci, Umut;Ozturk, Turkan;Bilici, Ahmet;Tastekin, Didem;Ozdemir, Nuriye;Unal, Olcun Umit;Oflazoglu, Utku;Turkmen, Esma;Erdogan, Bulent;Uyeturk, Ummugul;Oksuzoglu, Berna;Cinkir, Havva Yesil;Yasar, Nurgul;Gumus, Mahmut

  • Published : 2013.12.31

Abstract

Background: Inoperable and metastatic hepatocellular carcinoma (HCC) is associated with a poor prognosis and low chemotherapeutic efficiency. Sorafenib is an oral multi-kinase inhibitor exerting its effects via the RAF/MEK/ERK pathway, vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor beta (PDGFR-${\beta}$) tyrosine kinases. Randomized studies have shown a significant contribution of sorafenib to life expectancy and quality of life of cancer patients. The aim of the present study is to evaluate the efficacy and side effects of sorafenib therapy in Turkey. Materials and Methods: Data for 103 patients (82 males, 21 females) receiving sorafenib therapy in 13 centers from February 2008 to December 2012 were evaluated. Median age was 61 years and median ECOG performance status was 1 (range: 0-2). 60 patients (58%) had hepatitis B, 15 patients (15%) had hepatitis C infection and 12 patients (12%) had a history of alcohol consumption. All of the patients had Child scores meeting the utilization permit of the drug in our country (Child A). Results: A total of 571 cycles of sorafenib therapy were administered with a median of four per patient. Among the evaluable cases, there was partial response in 15 (15%), stable disease in 52 (50%), and progressive disease in 36 (35%). Median progression-free survival was 18 weeks and median overall survival was 48 weeks. The dose was reduced only in 6 patients and discontinued in 2 patients due to grade 3-4 toxicity, 18 patients (17%) suffering hand-foot syndrome, 7 (7%) diarrhea, and 2 (2%) vomiting. Conclusions: This retrospective study demonstrated better efficacy of sorafenib therapy in patients with advanced HCC compared to the literature while progression-free survival and overall survival findings were comparable. The side effect rates indicate that the drug was tolerated well. In conclusion, among the available treatment options, sorafenib is an efficient and tolerable agent in patients with inoperable or metastatic HCC.

Keywords

Hepatocellular carcinoma;sorafenib;Turkey

References

  1. Bai W, Wang YJ, Zhao Y, et al (2013). Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. J Dig Dis, 14, 181-90. https://doi.org/10.1111/1751-2980.12038
  2. Brunocilla PR, Brunello F, Carucci P, et al (2013). Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol, 30, 345. https://doi.org/10.1007/s12032-012-0345-2
  3. Chang MH, Chen CJ, Lai MS, et al (1997). Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med, 336, 1855-9. https://doi.org/10.1056/NEJM199706263362602
  4. Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised,doubleblind, placebo-controlled trial. Lancet Oncol, 10, 25-34. https://doi.org/10.1016/S1470-2045(08)70285-7
  5. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  6. European Association for Study of Liver; European Organisation for Research and Treatment of Cancer (2012). EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer, 48, 599-641. https://doi.org/10.1016/j.ejca.2011.12.021
  7. Ezzoukhry Z, Louandre C, Trecherel E, et al (2012). EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer, 131, 2961-9. https://doi.org/10.1002/ijc.27604
  8. Huynh H, Nguyen TT, Chow KH, et al (2003). Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol, 3, 19. https://doi.org/10.1186/1471-230X-3-19
  9. Kostner AH, Sorensen M, Olesen RK, et al (2013). Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability. ScientificWorld Journal, 2013, 931972.
  10. Llovet JM, Ricci S, Mazzaferro V, et al (2008); Sharp investigators study group. sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90. https://doi.org/10.1056/NEJMoa0708857
  11. Oliveri RS, Wetterslev J, Gluud C (2011). Transarterial(chemo) embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev, 16, 4787.
  12. Schmitt M, Horbach A, Kubitz R, et al (2004). Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol, 41, 274-83 https://doi.org/10.1016/j.jhep.2004.04.035
  13. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  14. Stock P, Monga D, Tan X, et al (2007). Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther, 6, 1932-41.
  15. Zhu AX, Rosmorduc O., Evans J, et al (2012). A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). 37th ESMO Congress; Vienna, Austria. European Society Med Oncol.

Cited by

  1. Clinical Significance of Joint Detection of Serum VEGF, SIL-2R and HGF in Patients with Primary Hepatocellular Carcinoma before and after Percutaneous Microwave Coagulation Therapy vol.15, pp.11, 2014, https://doi.org/10.7314/APJCP.2014.15.11.4545
  2. Differential Expression of IQGAP1/2 in Hepatocellular Carcinoma and its Relationship with Clinical Outcomes vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4951
  3. Efficacy and Safety of Sorafenib for Advanced Non-Small Cell Lung Cancer: a Meta-analysis of Randomized Controlled Trials vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5691
  4. Clinical Study of Hepatectomy Combined with Jianpi Huayu Therapy for Hepatocellular Carcinoma vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5951
  5. Sorafenib Continuation after First Disease Progression Could Reduce Disease Flares and Provide Survival Benefits in Patients with Hepatocellular Carcinoma: a Pilot Retrospective Study vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3151
  6. Schedule-Dependent Effects of Kappa-Selenocarrageenan in Combination with Epirubicin on Hepatocellular Carcinoma vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3651
  7. Health-Related Quality of Life of Patients with Intermediate Hepatocellular Carcinoma after Liver Resection or Transcatheter Arterial Chemoembolization vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4451
  8. Activation of Caspase-9/3 and Inhibition of Epithelial Mesenchymal Transition are Critically Involved in Antitumor Effect of Phytol in Hepatocellular Carcinoma Cells vol.29, pp.7, 2015, https://doi.org/10.1002/ptr.5342
  9. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis vol.17, pp.1, 2017, https://doi.org/10.1186/s12885-017-3707-5
  10. Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals vol.8, pp.10, 2017, https://doi.org/10.1038/cddis.2017.411
  11. Regulation of SIRT1/AMPK axis is critically involved in gallotannin-induced senescence and impaired autophagy leading to cell death in hepatocellular carcinoma cells pp.1432-0738, 2017, https://doi.org/10.1007/s00204-017-2021-y
  12. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence vol.13, pp.2, 2016, https://doi.org/10.3892/ol.2016.5525
  13. altering the pSTAT3-CCL2/Bcl2 signals vol.140, pp.3, 2016, https://doi.org/10.1002/ijc.30446
  14. Wogonin Suppresses the Activity of Matrix Metalloproteinase-9 and Inhibits Migration and Invasion in Human Hepatocellular Carcinoma vol.23, pp.2, 2018, https://doi.org/10.3390/molecules23020384
  15. Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study vol.6, pp.5, 2018, https://doi.org/10.12998/wjcc.v6.i5.74